Emerging Peptide Research: Compounds to Watch in 2026

If semaglutide (GLP-1 agonist) was the first wave and tirzepatide (GIP/GLP-1 dual agonist) was the second, 2026 is seeing the emergence of triple-receptor agonists and other multi-target peptides:

Retatrutide (LY3437943) Developed by Eli Lilly, retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase II trial data showed remarkable weight loss results — up to 24% body weight reduction at 48 weeks with the highest dose. The glucagon receptor component adds a thermogenic (calorie-burning) effect on top of the appetite-suppressing and insulin-sensitising actions of GIP and GLP-1 activation.

Phase III trials are underway, and if results confirm Phase II findings, retatrutide could represent a significant advance over both semaglutide and tirzepatide. The addition of glucagon receptor agonism is particularly interesting because it addresses energy expenditure — not just energy intake.

Survodutide (BI 456906) Developed by Boehringer Ingelheim, survodutide is a dual GLP-1/glucagon agonist (note: different receptor pairing than tirzepatide). It's being investigated primarily for MASH (metabolic dysfunction-associated steatohepatitis) and obesity. Early clinical data shows impressive liver fat reduction alongside significant weight loss, potentially positioning it as a preferred option for patients with both obesity and liver disease.

CagriSema Novo Nordisk's combination of cagrilintide (an amylin analogue) with semaglutide, administered as a single weekly injection. The REDEFINE Phase III programme has shown weight loss results exceeding semaglutide alone, leveraging amylin's distinct appetite-suppressing mechanism alongside GLP-1 agonism. This represents a combination approach rather than a single multi-receptor molecule.

How peptides are delivered is evolving as rapidly as the peptides themselves:

Oral peptide delivery The success of oral semaglutide (Rybelsus) has proven that oral peptide delivery is commercially viable, and multiple companies are now developing oral formulations for other peptides: - Oral tirzepatide — Eli Lilly is developing an oral formulation that could eliminate the need for weekly injections - Oral GLP-1 agonists from other manufacturers — Several companies are developing oral GLP-1 competitors using novel absorption enhancement technologies - SNAC and other permeation enhancers — The sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) technology used in Rybelsus is being adapted for other peptides

Implantable and depot formulations Long-acting depot formulations that release peptides over weeks or months are in development: - Subcutaneous implants that slowly release GLP-1 agonists over 6-12 months - Biodegradable microsphere injections providing sustained peptide release - These could dramatically improve adherence by reducing dosing to a few times per year

Transdermal delivery Microneedle patches and other transdermal technologies are being developed to deliver peptides through the skin painlessly: - Dissolving microneedle patches that deposit peptides in the dermis - Iontophoretic patches that use mild electrical current to drive peptide absorption - These approaches could make peptide administration as simple as applying a patch

Nasal delivery Intranasal peptide delivery offers rapid absorption through the nasal mucosa, with potential for faster onset of action than subcutaneous injection. Several peptide nasal sprays are in development, particularly for peptides targeting the central nervous system.

Perhaps the most transformative trend in peptide research is the application of artificial intelligence and machine learning to peptide design:

De novo peptide design AI models can now design novel peptide sequences optimised for specific receptor targets, stability, and pharmacokinetic properties. This represents a fundamental shift from traditional peptide discovery (which relied on identifying natural peptides and modifying them) to computationally designed molecules with no natural equivalent.

Key developments: - AlphaFold-based approaches — Building on DeepMind's protein structure prediction breakthrough, researchers are using structural prediction tools to design peptides that fit specific receptor binding sites with unprecedented precision - Generative models — Large language models trained on peptide sequence data can generate novel peptide candidates optimised for specific properties (binding affinity, selectivity, stability, half-life) - High-throughput screening acceleration — AI can predict which peptide candidates are most likely to succeed, dramatically reducing the time and cost of experimental screening

Antimicrobial peptides (AMPs) AI-designed antimicrobial peptides represent one of the most advanced applications. With antibiotic resistance growing globally, AI has been used to design novel AMPs that kill resistant bacteria through mechanisms distinct from traditional antibiotics. Several AI-designed AMPs are now in preclinical testing.

Personalised peptide therapeutics Looking further ahead, AI could enable personalised peptide design — creating peptide sequences optimised for an individual's genetic profile, receptor variants, and metabolic characteristics. While still theoretical, this represents the convergence of peptide science, genomics, and artificial intelligence.

The implications: AI-designed peptides could dramatically accelerate the pipeline from discovery to clinical application. Where traditional peptide development takes 10-15 years from initial discovery to approval, AI-assisted approaches could compress this timeline significantly — potentially bringing novel peptide therapeutics to patients faster than ever before.

Beyond specific compounds, several broader research areas are gaining momentum in 2026:

Neurological applications: Peptides targeting neurological conditions are an increasingly active research area: - Neuroprotective peptides — Compounds like Semax and Selank continue to be studied for cognitive enhancement and neuroprotection - Peptides for neurodegeneration — GLP-1 agonists (including semaglutide) are being investigated for Alzheimer's and Parkinson's disease, with early clinical data showing promising neuroprotective effects - Blood-brain barrier penetrating peptides — Novel peptide shuttles that can cross the BBB are enabling drug delivery to the central nervous system

Longevity and ageing: The intersection of peptide research and longevity science is producing interesting developments: - Epithalon (a synthetic tetrapeptide analogue of Epitalon) continues to be studied for its potential effects on telomerase activity - GHK-Cu genome-wide expression studies suggest it may reset gene expression patterns toward a more youthful profile - NAD+ precursor peptides — Novel peptide formulations designed to enhance cellular NAD+ levels are in early development

Immunomodulation: Peptide-based approaches to immune modulation are advancing: - Thymosin Alpha-1 — Clinical applications in immune support continue to expand - Peptide vaccines — Short peptide sequences representing viral or tumour epitopes are being developed as next-generation vaccines - Autoimmune disease — Tolerogenic peptides designed to retrain the immune system in autoimmune conditions are in clinical trials

Tissue engineering and regenerative medicine: Self-assembling peptides that form scaffolds for tissue regeneration represent a frontier application: - Peptide hydrogels for wound healing and tissue repair - Injectable peptide scaffolds for cartilage and bone regeneration - Peptide-based biomaterials for nerve repair and cardiac tissue engineering

The big picture: Peptide research in 2026 is characterised by convergence — combining advances in AI, multi-receptor pharmacology, novel delivery systems, and expanded therapeutic applications. The field is moving beyond individual compounds toward integrated platforms that could transform how we approach metabolic disease, neurodegeneration, infection, and ageing.